Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Mr Atul Verma
Dr. Paulus Kirchhof,
By Atul Verma, (Newmarket, Canada)View Discussant report
Read the press releaseOpen the PresentationWatch the Webcast
List of Authors: A. Verma (1), C-Y. Jiang (2), TR. Betts (3), J. Chen (4), I. Deisenhofer (5), R. Mantovan (6), L. Macle (7), C. Morillo (8), P. Sanders (9)(1) Southlake Regional Health Centre, Cardiology, Newmarket, Canada (2) Sir Run Run Hospital of Zhejiang University, Cardiology, Hangzhou, China, People's Republic of (3) John Radcliffe Hospital, Cardiology, Oxford, United Kingdom (4) Haukeland University Hospital, Cardiology, Bergen, Norway (5) German Heart Center of Munich, Cardiology, Munich, Germany (6) Hospital Santa Maria di Ca Foncello, Treviso, Italy (7) Montreal Heart Institute, Montreal, Canada (8) McMaster University, Hamilton, Canada (9) Royal Adelaide Hospital, Adelaide, Australia
BackgroundAblation of persistent atrial fibrillation (AF) is challenging. The optimal catheter ablation strategy for persistent AF is unknown. Guidelines suggest that additional substrate modification in addition to pulmonary vein isolation (PVI) is required. The STAR AF 2 (Substrate and Trigger Ablation for Reduction of AF) trial compared 3 strategies of ablation: PVI, PVI plus complex fractionated electrograms (CFE), and PVI plus linear ablation (LINES) (ClinicalTrials.gov NCT01203748). MethodsPatients undergoing a first ablation procedure for drug-refractory persistent AF (defined as episodes lasting more than 7 days) were randomized 1:4:4 to each of the three strategies at 48 sites in 12 countries. For PVI (n=67), all PV antra were isolated guided by a circular mapping catheter with confirmed entrance and exit block. For PVI+CFE (n=263), PVI was followed by AF induction and total elimination of electrograms demonstrating complex activity (or until AF terminated to sinus). For PVI+LINES (n=259), PVI was followed by linear ablation along the left atrial roof and along the mitral isthmus with confirmation of bidirectional block. Repeat procedures using the identical strategy as first ablation were allowed between 3-6 months. Patients were followed at 3, 6, 9, 12 and 18 months with a visit & 48 hr Holter. Weekly & symptomatic transtelephonic monitoring was performed for 18 months. The primary endpoint was time to first documented AF >30 seconds after a single ablation procedure. ResultsA total of 589 patients with persistent AF were included (79% male, age 60±9 years, LA size 45±6 mm). Most patients (76%) were continuously in AF for >6 months pre-ablation (median duration of continuous AF 2.2 years, IQR 0.9-4.8). At the time of ablation, 79% of patients were in spontaneous AF. Successful PVI was achieved in 97% of all patients with no differences between groups. For PVI+CFE, CFE were successfully mapped and ablated in 80% (11% could not be mapped because AF was non-inducible after PVI); for PVI+LINES, 74% had successful lines with bidirectional block. Acute AF termination occurred in 45% of PVI+CFE, 22% of PVI+LINES and 8% of PVI (p<0.0001). Procedure time was significantly shorter for PVI (167±55 min) compared to PVI+CFE (229±83 min) and PVI+LINES (223±89 min) (p<0.0001). After 18 months, 59% of patients randomized to PVI were free from any documented AF after a single ablation compared to 48% for PVI+CFE and 44% for PVI+LINES (p=0.15). When atrial flutter and tachycardia recurrences were counted in addition to AF, there was still no difference between the 3 arms after a single procedure. Repeat ablation was performed in 29% of all patients with no significant difference between groups. Complications included tamponade (0.2%), TIA (0.5%), and 1 atrio-esophageal fistula. ConclusionsCatheter ablation with PVI achieves reasonable outcomes in persistent AF. The addition of further substrate ablation with either CFE or LINES increases procedural time, but offers no additional benefit over PVI alone.
By Paulus Kirchhof, FESC (Birmingham, United Kingdom)See Presenter abstract
Open the presentationWatch the Webcast
Hot Line: Heart failure: devices and interventions
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved